Monsenso supports UK research on treatment-resistant depression
Copenhagen, Denmark
Monsenso delivers digital research platform for groundbreaking UK project on treatment-resistant depression.
Monsenso A/S is proud to announce its strategic role as the digital technology partner for the DECODE project in the United Kingdom. The initiative, led by the University of Birmingham, in collaboration with the Mental Health Mission Midlands Translational Centre, Birmingham and Solihull NHS Foundation Trust, and Nottinghamshire Healthcare NHS Foundation Trust, is focused on transforming clinical research and care for patients with treatment-resistant depression (TRD).
As part of the project, Monsenso’s digital platform will enable stratified recruitment, remote data collection, and standardised clinical endpoint measurement across multiple NHS sites — laying the groundwork for improved precision in depression research and future interventions.
Addressing a Critical Public Health Challenge
Treatment-resistant depression (TRD) affects almost half of patients diagnosed with major depressive disorder meaning they do not respond to two or more oral antidepressants, and TRD is associated with poorer outcomes, including high comorbidity, suicidality, and economic burden.
The DECODE project aims to build a digitally enabled recruitment and monitoring infrastructure to better identify, understand, and ultimately treat this complex condition.
Recruitment is expected to begin in Q3 2025, with Monsenso’s platform playing a pivotal role in data collection and patient stratification.
Quote from Monsenso CEO
“We are honoured to support such an important national initiative addressing one of the most challenging areas in mental health. Monsenso’s platform is designed to help healthcare providers and researchers make better, data-driven decisions through real-time digital monitoring and standardised assessments,” said Thomas Lethenborg, CEO of Monsenso.
“This project reaffirms our strategic positioning as a trusted partner in supporting decentralised, real-world data studies across Europe with healthcare, academic institutions and pharmaceuticals.”
Strategic Importance for Monsenso
- Expansion into the UK: Strengthens Monsenso’s footprint within the UK healthcare ecosystem, particularly within the NHS and leading academic partners.
- Scalable digital, decentralised research model: Demonstrates the scalability and flexibility of Monsenso’s platform for decentralised multi-site health research.
- Expansion possibilities: If successful, the DECODE project has potential to pave the way for geographic expansion and follow-on precision-medicine studies.
- Validation of product-market fit: Reinforces Monsenso’s role in delivering regulated, patient-centric digital tools that meet the complex needs of decentralised, real-world studies in psychiatric conditions and beyond.
Academic and Clinical Endorsement
Professor Steven Marwaha, Co-director of the Midlands Mental Health Mission and Professor at the University of Birmingham, stated:
“This partnership with Monsenso enables us to streamline and enhance the way we recruit patients and assess outcomes. By integrating continuous data collection, digital phenotyping tools and standardising clinical endpoints, we can accelerate our understanding of treatment-resistant depression and drive more precise and personalised future interventions.
Click the button below for more information about the Monsenso solution.